Hypercalcemia clinical trials at UC Health
1 research study open to eligible people
Experimental combination medicine for Treating Patients With Relapsed or Refractory Multiple Myeloma
open to eligible people ages 18 years and up
This phase I trial studies the side effects and best dose of MDM2 inhibitor AMG-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back of has not responded to previous treatment. Drugs used in chemotherapy, such as MDM2 inhibitor AMG-232, carfilzomib, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
at UC Davis